Merck and AstraZeneca announced on December 11, 2024, positive long-term results from the OlympiA Phase 3 trial. The trial evaluated Lynparza (olaparib) in people with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer.
The data demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS), and distant disease-free survival (DDFS). After six years, the OS rate was 87.5% compared to 83.2% in the placebo group.
These results confirm that adjuvant treatment with Lynparza for one year continues to deliver significant survival benefits. This reinforces the importance of germline BRCA testing at diagnosis to identify eligible patients who may benefit from Lynparza treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.